Ultra-LEAF™ Purified anti-human CD3 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, et al. 2005. Immunology 116:487.
5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed

Product Citations

1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
2. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
3. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
4. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
5. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
6. Hsiue EH, et al. 2021. Science. 371:. PubMed
7. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
8. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
9. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
10. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
11. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
12. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
13. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
14. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
15. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
16. Fang F, et al. 2022. JCI Insight. 7:. PubMed
17. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
18. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
19. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
20. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
21. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
22. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
23. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
24. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
25. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
26. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
27. Saragovi A, et al. 2020. Elife. 9:00. PubMed
28. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
29. Han K, et al. 2021. Nat Metab. 3:318. PubMed
30. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
31. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
32. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
33. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
34. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
35. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
36. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
37. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
38. Sekine T, et al. 2020. Cell. 183:158. PubMed
39. Sun T, et al. 2019. Haematologica. 105:661. PubMed
40. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
41. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
42. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
43. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
44. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
45. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
46. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
47. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
48. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
49. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
50. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
51. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
52. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
53. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
54. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
55. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
56. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
57. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
58. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
59. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
60. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed

RRID

AB_2749889 (BioLegend Cat. No. 317350)
AB_2749888 (BioLegend Cat. No. 317349)
AB_2571995 (BioLegend Cat. No. 317348)
AB_11147370 (BioLegend Cat. No. 317325)
AB_11150592 (BioLegend Cat. No. 317326)
AB_2571994 (BioLegend Cat. No. 317347)

Antigen Details

Structure

Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD

Distribution

Mature T and NK T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol
• T Cell Activation with anti-CD3 Antibodies Protocol - Human
• T Cell Activation with anti-CD3 Antibodies Protocol - Mouse

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis